ClinicalTrials.gg
CompletedNCT05132088OASIS 2Updated Aug 14, 2026Results posted

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

A Phase 3 interventional study of semaglutide 50 mg and placebo (semaglutide) in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
37th of 143
201 · median 100
Started
2021
with 9 others
Phase 3
42 of 143
10 open now
Registered
40th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 37th largest by enrollment, is one of 10 that started in 2021, is one of 42 in phase 3, and was the 40th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight.

This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation.

Semaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes.

Participants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning.

In addition to taking the medicine, participants will have talks with study staff about:

  • healthy food choices
  • how to be more physically active
  • what participants can do to lose weight The study will last for about 1½ year. Participants will have 14 clinic visits and 7 phone calls with the study healthcare professional.

Blood samples will be taken at 12 visits. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. If participants are a woman and are able to become pregnant, participants will be checked for pregnancy via urine tests.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 201 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female, age above or equal to 18 years at the time of signing informed consent
  • (BMI) of greater than or equal to 27.0 kg/m\^2 with greater than or equal to 2 weight related comorbidities (treated or untreated) according to the JASSO guideline or BMI greater than or equal to 35.0 kg/m\^2 with greater than or equal to1 weight related comorbidity (treated or untreated) according to the JASSO guideline. At least one comorbidity should be hypertension, dyslipidaemia or type 2 diabetes (T2D)
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1-4:

  • Diagnosed with T2D greater than or equal to 180 days prior to screening
  • Treated with either diet and exercise alone or stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OADs) alone or in any combination (metformin, α-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucose co-transporter 2 inhibitor) or thiazolidinediones)
  • 7.0-10.0% (53-86 mmol/mol) (both inclusive) as measured by central laboratory at screening

Exclusion criteria

Exclusion criteria:

Participants without T2D only:

  • greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes
  • Treatment with glucose-lowering agent(s) within 90 days prior to screening
  • Renal impairment measured as estimated (eGFR) value of eGFR brlow 15 ml/min/1.73 m\^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO) 2012 classification by the central laboratory at screening

Participants with T2D at screening only:

  • Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within the past 60 days prior to screening
  • Receipt of any other anti-diabetic drug within 90 days prior to screening for this study, or receipt of any investigational drugs not affecting diabetes within 30 days prior to screening for this study
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Renal impairment measured as eGFR value of below 30 mL/min/1.73 m\^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening
  • In participants treated with SGLT2i, renal impairment measured as eGFR value of below 60 mL/min/1.73 m\^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening

The following criteria apply to all participants:

Obesity-related:

  • Treatment with any medication indicated for weight management within 90 days prior to screening
  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening, (2) lap banding, if the band has been removed greater than 1 year prior to screening, (3) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed greater than 1 year prior to screening
  • Uncontrolled thyroid disease per investigators discretion
  • A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    oral semaglutide 50 mg once daily

    All participants will get semaglutide or placebo tablets, 1 tablet every morning.

    Drug: semaglutide 50 mg

  • Placebo comparator
    oral semaglutide placebo once daily

    All participants will get semaglutide or placebo tablets, 1 tablet every morning.

    Drug: placebo (semaglutide)

Interventions

  • Participants will have semaglutide for 68 weeks and will have 1 tablet every morning. Dose gradually increased to 50 mg.

  • Drugplacebo (semaglutide)

    Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Percent change in body weight from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

    Time frame: Baseline (week 0), week 68

  2. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)

    Number of participants who achieved \>=5% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

    Time frame: At week 68

Secondary outcomes

  1. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)

    Number of participants who achieved \>=10% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

    Time frame: At week 68

  2. Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score

    The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patient's quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participant's overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results for Physical Function Domain are presented in this outcome measure. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

    Time frame: Baseline (week 0), week 68

  3. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)

    Number of participants who achieved \>=15% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. The outcome measure was evaluated based on in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: At week 68

  4. Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)

    Number of participants who achieved \>=20% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. The outcome measure was evaluated based on in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: At week 68

  5. Change From Baseline in Body Mass Index (BMI)

    Change in BMI from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  6. Change From Baseline in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline

    Change in waist circumference measured according to JASSO guideline from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  7. Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (%)

    Change in VFA measured by CT Scan in a subset of the japanese study population from baseline (week 0) to week 68 is presented in %. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  8. Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (Centimeter Square [cm^2])

    Change in VFA measured by CT Scan in a subset of the japanese study population from baseline (week 0) to week 68 is presented in cm\^2. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  9. Change From Baseline in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  10. Change From Baseline in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  11. Change From Baseline in Glycosylated Haemoglobin (HbA1c)

    Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  12. Change From Baseline in Total Cholesterol: Ratio to Baseline

    Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  13. Change From Baseline in High-Density Lipoproteins (HDL): Ratio to Baseline

    Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  14. Change From Baseline in Low-Density Lipoproteins (LDL): Ratio to Baseline

    Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  15. Change From Baseline in Very Low-Density Lipoproteins (VLDL): Ratio to Baseline

    Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  16. Change From Baseline in Triglycerides: Ratio to Baseline

    Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  17. Change From Baseline in Free Fatty Acids: Ratio to Baseline

    Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

    Time frame: Baseline (week 0), week 68

  18. Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) : Ratio to Baseline

    Change in hsCRP measured as milligrams per liter (mg/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

    Time frame: Baseline (week 0), week 68

  19. Number of Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment: the date of first trial product administration (week 0) to the date of last trial product administration (week 68) excluding potential off-treatment time intervals of more than 3 consecutive days. For the evaluation of adverse events the lag time for each on-treatment time interval is 7 weeks.

    Time frame: Week 0 to week 75

  20. Number of Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 75 is presented based on the on-treatment observation, which was defined as the date of first trial product administration (week 0) to the date of last trial product administration (week 68) excluding potential off-treatment time intervals of more than 3 consecutive days. For the evaluation of adverse events the lag time for each on-treatment time interval is 7 weeks.

    Time frame: Week 0 to week 75

08

Results

Posted Aug 14, 2026

Participant flow

The trial was conducted at 13 sites in 2 countries as follows: Japan (9 sites) and South Korea (4 sites).

Participant flow — Overall Study
MilestoneOral Semaglutide 50 mgOral Semaglutide Placebo
Started13467
Full analysis set13467
Safety analysis set13466
Completed13064
Not completed43
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up20

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Percent change in body weight from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Percent change of body weight
Percent Change From Baseline in Body Weight
Percent change of body weightOral Semaglutide 50 mgOral Semaglutide Placebo
Percent Change From Baseline in Body Weight-14.9 ± 9.5-1.5 ± 5.0
Statistical analysis
  • Oral Semaglutide 50 mg vs Oral Semaglutide Placebo · ANCOVA · p = <0.0001 · Treatment difference: -13.07 · 95% CI -15.61 to -10.52
PrimaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)

Number of participants who achieved \>=5% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

Time frame:
At week 68
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)
ParticipantsOral Semaglutide 50 mgOral Semaglutide Placebo
Yes10711
No2053
Statistical analysis
  • Oral Semaglutide 50 mg vs Oral Semaglutide Placebo · Regression, Logistic · p = <0.0001 · Treatment odds ratio: 23.00 · 95% CI 10.28 to 51.42
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)

Number of participants who achieved \>=10% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

Time frame:
At week 68
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)
ParticipantsOral Semaglutide 50 mgOral Semaglutide Placebo
Yes836
No4458
SecondaryChange From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score

The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patient's quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participant's overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results for Physical Function Domain are presented in this outcome measure. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Score on a scale
Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score
Score on a scaleOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score7.6 ± 19.51.9 ± 15.2
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)

Number of participants who achieved \>=15% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. The outcome measure was evaluated based on in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
At week 68
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)
ParticipantsOral Semaglutide 50 mgOral Semaglutide Placebo
Yes600
No6764
SecondaryNumber of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)

Number of participants who achieved \>=20% weight reduction at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. The outcome measure was evaluated based on in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
At week 68
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)
ParticipantsOral Semaglutide 50 mgOral Semaglutide Placebo
Yes410
No8664
SecondaryChange From Baseline in Body Mass Index (BMI)

Change in BMI from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Kilogram per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
Kilogram per square meter (kg/m^2)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Body Mass Index (BMI)-4.89 ± 3.18-0.47 ± 1.71
SecondaryChange From Baseline in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline

Change in waist circumference measured according to JASSO guideline from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Centimeter (cm)
Change From Baseline in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline
Centimeter (cm)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline-11.2 ± 8.2-1.4 ± 4.4
SecondaryChange From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (%)

Change in VFA measured by CT Scan in a subset of the japanese study population from baseline (week 0) to week 68 is presented in %. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Percentage change of VFA
Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (%)
Percentage change of VFAOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (%)-35.1 ± 31.30.6 ± 21.4
SecondaryChange From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (Centimeter Square [cm^2])

Change in VFA measured by CT Scan in a subset of the japanese study population from baseline (week 0) to week 68 is presented in cm\^2. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Centimeter square (cm^2)
Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (Centimeter Square [cm^2])
Centimeter square (cm^2)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Visceral Fat Area (VFA) Measured by CT Scan in a Subset of the Japanese Study Population (Centimeter Square [cm^2])-0.06 ± 0.150.02 ± 0.12
SecondaryChange From Baseline in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure
Millimeters of mercury (mmHg)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Systolic Blood Pressure-11 ± 14-2 ± 13
SecondaryChange From Baseline in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure
Millimeters of mercury (mmHg)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Diastolic Blood Pressure-6 ± 10-1 ± 11
SecondaryChange From Baseline in Glycosylated Haemoglobin (HbA1c)

Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Change in HbA1c (%)
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Change in HbA1c (%)Oral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c)-0.8 ± 0.8-0.0 ± 0.7
SecondaryChange From Baseline in Total Cholesterol: Ratio to Baseline

Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of total cholesterol
Change From Baseline in Total Cholesterol: Ratio to Baseline
Ratio of total cholesterolOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Total Cholesterol: Ratio to Baseline0.92 ± 14.61.02 ± 14.2
SecondaryChange From Baseline in High-Density Lipoproteins (HDL): Ratio to Baseline

Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of HDL
Change From Baseline in High-Density Lipoproteins (HDL): Ratio to Baseline
Ratio of HDLOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in High-Density Lipoproteins (HDL): Ratio to Baseline1.07 ± 16.41.03 ± 14.5
SecondaryChange From Baseline in Low-Density Lipoproteins (LDL): Ratio to Baseline

Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of LDL
Change From Baseline in Low-Density Lipoproteins (LDL): Ratio to Baseline
Ratio of LDLOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Low-Density Lipoproteins (LDL): Ratio to Baseline0.89 ± 23.61.02 ± 26.4
SecondaryChange From Baseline in Very Low-Density Lipoproteins (VLDL): Ratio to Baseline

Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of VLDL
Change From Baseline in Very Low-Density Lipoproteins (VLDL): Ratio to Baseline
Ratio of VLDLOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Very Low-Density Lipoproteins (VLDL): Ratio to Baseline0.74 ± 37.70.99 ± 35.0
SecondaryChange From Baseline in Triglycerides: Ratio to Baseline

Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of triglycerides
Change From Baseline in Triglycerides: Ratio to Baseline
Ratio of triglyceridesOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Triglycerides: Ratio to Baseline0.73 ± 40.20.99 ± 36.7
SecondaryChange From Baseline in Free Fatty Acids: Ratio to Baseline

Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site (week 75).

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of free fatty acids
Change From Baseline in Free Fatty Acids: Ratio to Baseline
Ratio of free fatty acidsOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in Free Fatty Acids: Ratio to Baseline0.91 ± 67.61.06 ± 61.3
SecondaryChange From Baseline in High Sensitivity C-Reactive Protein (hsCRP) : Ratio to Baseline

Change in hsCRP measured as milligrams per liter (mg/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial: the uninterrupted time interval from the date of randomisation (week 0) to the date of last contact with the study site.

Time frame:
Baseline (week 0), week 68
Reported as:
Geometric mean · Ratio of hsCRP
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) : Ratio to Baseline
Ratio of hsCRPOral Semaglutide 50 mgOral Semaglutide Placebo
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) : Ratio to Baseline0.45 ± 157.10.82 ± 153.9
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment: the date of first trial product administration (week 0) to the date of last trial product administration (week 68) excluding potential off-treatment time intervals of more than 3 consecutive days. For the evaluation of adverse events the lag time for each on-treatment time interval is 7 weeks.

Time frame:
Week 0 to week 75
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsOral Semaglutide 50 mgOral Semaglutide Placebo
Number of Treatment Emergent Adverse Events (TEAEs)608240
SecondaryNumber of Serious Adverse Events (SAEs)

A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 75 is presented based on the on-treatment observation, which was defined as the date of first trial product administration (week 0) to the date of last trial product administration (week 68) excluding potential off-treatment time intervals of more than 3 consecutive days. For the evaluation of adverse events the lag time for each on-treatment time interval is 7 weeks.

Time frame:
Week 0 to week 75
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsOral Semaglutide 50 mgOral Semaglutide Placebo
Number of Serious Adverse Events (SAEs)87

Adverse events

Collected over Week 0 to week 75. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Semaglutide 50 mg0/134 (0%)8/134 (6%)106/134 (79.1%)
Oral Semaglutide Placebo0/66 (0%)6/66 (9.1%)47/66 (71.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventOral Semaglutide 50 mgOral Semaglutide Placebo
AppendicitisInfections and infestations0/1341/66
Atrial fibrillationCardiac disorders0/1341/66
Carpal tunnel syndromeNervous system disorders0/1341/66
CataractEye disorders0/1341/66
Hepatic enzyme increasedInvestigations0/1341/66
Myofascial pain syndromeMusculoskeletal and connective tissue disorders0/1341/66
Radius fractureInjury, poisoning and procedural complications0/1341/66
Abdominal pain upperGastrointestinal disorders1/1340/66
DiverticulitisInfections and infestations1/1340/66
Inguinal herniaGastrointestinal disorders1/1340/66
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOral Semaglutide 50 mgOral Semaglutide Placebo
COVID-19Infections and infestations41/13422/66
NauseaGastrointestinal disorders34/1345/66
NasopharyngitisInfections and infestations15/13415/66
ConstipationGastrointestinal disorders28/1346/66
DiarrhoeaGastrointestinal disorders22/1346/66
PyrexiaGeneral disorders16/13410/66
VomitingGastrointestinal disorders20/1342/66
Tooth fractureInjury, poisoning and procedural complications1/1346/66
ArthralgiaMusculoskeletal and connective tissue disorders10/1342/66
HyperaesthesiaNervous system disorders10/1340/66

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Oral Semaglutide 50 mgOral Semaglutide PlaceboTotal
Mean50 ± 1149 ± 1249 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Oral Semaglutide 50 mgOral Semaglutide PlaceboTotal
Female533487
Male8133114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Semaglutide 50 mgOral Semaglutide PlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino13367200
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Semaglutide 50 mgOral Semaglutide PlaceboTotal
American Indian or Alaska Native000
Asian13467201
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
09

Study locations

15 sites
  • Shinsapporo Seiryou Hospital_General Clinical Department
    Sapporo, Hokkaido 004-0004, Japan
  • Tsuruma Kaneshiro Diabetes Clinic_Internal medicine
    Yamato-shi, Kanagawa 242-0004, Japan
  • OCROM Clinic_Internal medicine
    Suita-shi, Osaka 565-0853, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Toranomon Hospital, Endocrinology and Metabolism
    Minato-ku, Tokyo, 105-8470, Japan
  • The University of Osaka Hospital_Metabolic Medicine
    Osaka, 565-0871, Japan
  • Takatsuki Red Cross Hospital_Diabetes and Endocrine Div.
    Osaka, 569-1045, Japan
  • Takatsuki Red Cross Hospital
    Osaka, 569-1045, Japan
  • Tokyo Center Clinic_Internal Medicine
    Tokyo, 103-0028, Japan
  • Tokyo Center Clinic
    Tokyo, 103-0028, Japan
  • ToCROM Clinic_Internal Medicine
    Tokyo, 160-0008, Japan
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Kyungpook National University Hospital
    Daegu, 41944, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
10

References and documents

Publications

  • Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK; OASIS 2 Investigators. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. JAMA Intern Med. 2025 Oct 1;185(10):1206-1217. doi: 10.1001/jamainternmed.2025.3599. PubMed 40758358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2023, 19 months.

Results were first posted in Aug 2026, 3 years 1 month after primary completion. A results delay was requested in Jun 2024.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 24, 2021
StartActual
Nov 16, 2021
Primary completionActual
Jul 11, 2023
CompletionActual
Sep 1, 2023
Results delay requested
Jun 27, 2024
Results first posted
Aug 14, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05132088
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Nov 16, 2021
Primary completion
Jul 11, 2023
Completion
Sep 1, 2023
Results posted
Aug 14, 2026
Last update
Aug 14, 2026

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion